Tag - UNCY

Developments

Unicycive announces positive topline results from pivotal clinical trial in hyperphosphatemia

Unicycive Therapeutics (NASDAQ:UNCY) announced positive initial results from the patient reported outcome survey conducted during its pivotal clinical trial of oxylanthanum carbonate (OLC) in patients with...

July 10, 2024

Markets

Maxim starts Unicycive Therapeutics at buy; PT $3

Maxim Group initiated coverage of Unicycive Therapeutics (NASDAQ:UNCY) with a “buy” rating and price target of $3. The stock closed at $1.07 on March 15. Unicycive is aiming to bring two key assets through clinical...

March 16, 2022

Tag - UNCY

Unicycive announces positive topline results from pivotal clinical trial in hyperphosphatemia

Maxim starts Unicycive Therapeutics at buy; PT $3

General

More